Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The agreement extends manufacturing commitments through 2033 and pushes Samsung Biologics’ cumulative contract value above $21.9 billion.
September 11, 2026
By: Charlie Sternberg
Editor’s Take: This deal comes as Samsung Biologics continues to secure long-term client commitments and fill available manufacturing capacity quickly.
Samsung Biologics has signed a $262 million manufacturing agreement with a European pharmaceutical company, according to a securities filing disclosed under Korean market rules.
The contract, which includes manufacturing commitments running through 2033, will be carried out at Samsung Biologics’ Songdo manufacturing site in South Korea. The company said the customer’s name and product-specific details will remain confidential under the terms of the agreement.
The new award underscores sustained demand for the company’s manufacturing capacity, with existing capacity across Samsung Biologics’ network continuing to be booked rapidly amid long-term demand from global biopharma clients.
Following the latest agreement, Samsung Biologics’ cumulative contract value has surpassed USD 21.9 billion, reinforcing the company’s business momentum as it expands capacity, broadens its portfolio, and builds out its global footprint.
In July, Samsung Biologics launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a global CDMO specializing in peptide-based APIs.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
